Pluripotent stem cell-derived natural killer cells for cancer therapy.

Department of Medicine and Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Translational research : the journal of laboratory and clinical medicine 09/2010; 156(3):147-54. DOI: 10.1016/j.trsl.2010.07.008
Source: PubMed

ABSTRACT Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide an accessible, genetically tractable, and homogenous starting cell population to efficiently study human blood cell development. These cell populations provide platforms to develop new cell-based therapies to treat both malignant and nonmalignant hematological diseases. Our group previously demonstrated the ability of hESC-derived hematopoietic precursors to produce functional natural killer (NK) cells as well as an explanation of the underlying mechanism responsible for the inefficient development of T and B cells from hESCs. hESCs and iPSCs, which can be engineered reliably in vitro, provide an important new model system to study human lymphocyte development and produce enhanced cell-based therapies with the potential to serve as a "universal" source of antitumor lymphocytes. This review will focus on the application of hESC-derived NK cells with currently used and novel therapeutics for clinical trials, barriers to translation, and future applications through genetic engineering approaches.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Blurring the boundary between innate and adaptive immune system, natural killer (NK) cells are widely recognized as potent anti-leukemia mediators. Alloreactive donor NK cells have been shown to improve the outcome of allogeneic stem-cell transplantation for leukemia. In addition, in vivo transfer of NK cells may soon reveal an important therapeutic tool for leukemia, if tolerance to NK-mediated anti-leukemia effects is overcome. This will require, at a minimum, the ex vivo generation of a clinically safe NK cell product containing adequate numbers of NK cells with robust anti-leukemia potential. Ideally, ex vivo generated NK cells should also have similar anti-leukemia potential in different patients, and be easy to obtain for convenient clinical scale-up. Moreover, optimal clinical protocols for NK therapy in leukemia and other cancers are still lacking. These and other issues are being currently addressed by multiple research groups. This review will first describe current laboratory NK cell expansion and differentiation techniques by separately addressing different NK cell sources. Subsequently, it will address the mechanisms known to be responsible for NK cell alloreactivity, as well as their clinical impact in the hematopoietic stem cells transplantation setting. Finally, it will briefly provide insight on past NK-based clinical trials.
    Frontiers in Immunology 03/2014; 5:95. DOI:10.3389/fimmu.2014.00095
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer cells and the immune system are closely related and thus influence each other. Although immune cells can suppress cancer cell growth, cancer cells can evade immune cell attack via immune escape mechanisms. Natural killer (NK) cells kill cancer cells by secreting perforins and granzymes. Upon contact with cancer cells, NK cells form immune synapses to deliver the lethal hit. Mature NK cells are differentiated from hematopoietic stem cells in the bone marrow. They move to lymph nodes, where they are activated through interactions with dendritic cells. Interleukin-15 (IL-15) is a key molecule that activates mature NK cells. The adoptive transfer of NK cells to treat incurable cancer is an attractive approach. A certain number of activated NK cells are required for adoptive NK cell therapy. To prepare these NK cells, mature NK cells can be amplified to obtain sufficient numbers of NK cells. Alternatively, NK cells can be differentiated and amplified from hematopoietic stem cells. In addition, the selection of donors is important to achieve maximal efficacy. In this review, we discuss the overall procedures and strategies of NK cell therapy against cancer.
    Experimental and Molecular Medicine 02/2015; 47(2):e141. DOI:10.1038/emm.2014.114 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Successful reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) has ushered in a new era of regenerative medicine. Several studies on iPSCs have corroborated their immense promise and potential for use in cell therapy and disease modeling. However, several shortcomings need to be overcome before they can be used in clinical therapy. Investigation of iPSC fate and physiology in vivo and ultimately, the feasibility of their application in cell transplantation therapy, requires more in-depth studies in living subjects. One recently established alternative approach to reprogramming involves the direct conversion of a terminally differentiated somatic cell of one type into another, without dedifferentiating into a pluripotent state. This direct lineage reprogramming strategy is significantly faster, has the potential to generate an enriched population of a specific subtype of cells, and hence, has wide implications in regenerative cell therapy. Here, we review recent advances in iPSC technology and summarize the research on the generation of patient-specific induced cell types using direct lineage conversion. Specifically, we focus on the scope of application of this approach in autologous cell replacement therapy for diabetic wound treatment.
    Molecular and Cellular Endocrinology 06/2014; 393(1-2). DOI:10.1016/j.mce.2014.05.025 · 4.24 Impact Factor

Full-text (2 Sources)

Available from
Nov 17, 2014